Effect of continuous renal replacement therapy on kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with septic acute kidney injury.
机构：[1]Intensive Care Unit,The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China[2]Department of Traditional Chinese Medicine,The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China
Kidney injury molecule-1 (Kim-1) and neutrophil gelatinase-associated lipocalin (NGAL) have been investigated as biomarkers for acute kidney injury (AKI). However, they are seldom investigated in patients with septic AKI treated with continuous renal replacement therapy (CRRT). The aim of the present study was to investigate the therapeutic effectiveness and possible mechanisms of CRRT in septic AKI by observing the changes in Kim-1 and NGAL levels. A group of 38 patients with septic AKI was randomly divided into the conventional drug treatment group (group A) and the CRRT group (group B). All patients were treated with standard antisepsis agents, and group B was additionally submitted to CRRT for 24 h. The levels of Kim-1 and NGAL in serum, urine and the ultrafiltrate of CRRT were measured prior to and at 12, 24, and 48 h after treatment. In group A, urinary Kim-1 (uKim-1) levels at 12, 24 and 48 h were lower than prior to treatment (P<0.05), whereas urinary NGAL (uNGAL) showed no difference among the various time points (P>0.05). In group B, uKim-1 was decreased at 24 and 48 h compared with before treatment (all P<0.05), whereas uNGAL was decreased at 48 h (P<0.05). Serum Kim-1 did not change with time in groups A and B (P>0.05), whereas serum NGAL was increased after treatment in group A (P<0.05) but did not change in group B (P>0.05). Kim-1 and NGAL were not detected in the ultrafiltrate of CRRT. uKim-1 and uNGAL decreased significantly after CRRT, and therefore may be used to reflect the change of renal function during CRRT and to evaluate the therapeutic effectiveness of the method.
基金：
Guangdong Province Science and Technology Social Development Projects (2013B021800075) and Zhanjiang Financial Fund Allocated for Competitive Scientific and Technological Projects (2012C0302-46).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|4 区医学
小类|4 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验
第一作者：
第一作者机构：[1]Intensive Care Unit,The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China[*1]Intensive Care Unit, The Affiliated Hospital of Guangdong Medical University, 57 Renmin South Street, Xiashan, Zhanjiang, Guangdong 524001, P.R. China
共同第一作者：
通讯作者：
通讯机构：[1]Intensive Care Unit,The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China[2]Department of Traditional Chinese Medicine,The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China[*1]Intensive Care Unit, The Affiliated Hospital of Guangdong Medical University, 57 Renmin South Street, Xiashan, Zhanjiang, Guangdong 524001, P.R. China[*2]Department of Traditional Chinese Medicine, The Affiliated Hospital of Guangdong Medical University, 57 Renmin South Street, Xiashan, Zhanjiang, Guangdong 524001, P.R. China
推荐引用方式(GB/T 7714)：
Shao Yiming,Fan Yinqiang,Xie Yuliu,et al.Effect of continuous renal replacement therapy on kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with septic acute kidney injury.[J].Experimental and therapeutic medicine.2017,13(6):3594-3602.doi:10.3892/etm.2017.4436.
APA：
Shao Yiming,Fan Yinqiang,Xie Yuliu,Yin Lu,Zhang Yuanli...&Zhao Shiman.(2017).Effect of continuous renal replacement therapy on kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with septic acute kidney injury..Experimental and therapeutic medicine,13,(6)
MLA：
Shao Yiming,et al."Effect of continuous renal replacement therapy on kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in patients with septic acute kidney injury.".Experimental and therapeutic medicine 13..6(2017):3594-3602
